INTRODUCTION AND OBJECTIVES:
The purpose of the study was to assess the feasibility of measuring telomerase activity in urinal sediment cells for non-invasive diagnosis of urinary bladder cancer (BC) and its relapses in the postoperative period.
METHODS: The study enrolled 50 patients with BC. The control group was composed of 40 patients. Thirty-eight patients of the study group were subjected to transurethral resection (TUR), 5 patients underwent open bladder resection and 7 patients endured radical cystectomy. Histological examination revealed non-invasive bladder cancer in 32 patients and invasion into the muscular layer in 18 of 50 patients. The control group consisted of patients with renal cysts, chronic cystitis and benign prostate hyperplasia.
To examine telomerase activity (TA), a total of 90 urine samples were taken from both the Study and Control group patients. TA in urine cells was determined by means of telomeric repeat amplification protocol (TRAP), real-time PCR and electrophoresis.
Forty-three patients with preserved urinary bladder were postoperatively followed up for one year with the examination of TA and control cystoscopies each 3 months.
RESULTS: In the Study group, TA was detected in 46 (92%) of the 50 urine specimens. In the control group, TA was revealed in 1 (0.4%) of the 40 patients. The obtained findings thus strongly suggest statistically significant prevalence of urinary bladder cancer patients with the presence of TA in urine (p[0.001).
We also revealed a correlation between TA and tumour differentiation. In 16 urine samples in patients with G1, the average TA amounted to 0.7%, in 20 urine samples in G2, the mean TA amounted to 0.98%, and in 10 urine samples in G3, the mean TA amounted to 1.33%. In stage G1 y [ -0.003463 þ 0.4700 x strong significant correlation (p[0.0003). In stage G2 y [ -0.01960 þ 0.5456 x strong significant correlation (p[0.0001). In stage G3 y [ 0.01370 þ 0.5395 x strong significant correlation (p[0.02). The sensitivity and specificity of the method amounted to 92% and 97.5%, respectively.
During the postoperative follow up of 43 patients with the preserved urinary bladder we revealed BC relapse in 17 patients (39.5%). TA in urine was present in 14 of 17 (82.35%) relapse cases and was negative in 3 of 17 cases (17.65%).
CONCLUSIONS: The preliminary data suggest the possibility of using telomerase activity in diagnosis of urinary bladder cancer and its relapses.
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MP63-06 COMPARATIVE DETERMINATION OF TERT MUTATIONS IN URINARY SEDIMENT DNA BY NGS AND DDPCR FOR BLADDER CANCER DETECTION
Friedrich Stoeckel, Karsten Salomo, Stasik Sebastian, Christian Thiede, Mario Menschikowski, Ulrike Heberling, Manfred P. Wirth, Susanne Fuessel*, Dresden, Germany INTRODUCTION AND OBJECTIVES: The determination of the two abundant point-mutations C228T and C250T in the TERT promoter in urine samples could potentially enhance the non-invasive detection of bladder cancer (BCa). Therefore, the applicability of two molecular biological detection methods -next-generation sequencing (NGS) and digital droplet PCR (ddPCR) -was compared with the voided urine cytology (VUC).
METHODS: Genomic DNA was isolated from urinary sediments from 49 histologically positive BCa patients and from 23 non-cancerous control subjects, comprising 13 patients with urolithiasis and 10 patients with unconfirmed BCa suspicion (noBCa). For the NGS analyses, a nested PCR procedure was used to amplify a TERT promoter fragment covering both mutations followed by unidirectional sequencing on an Ion Torrent PGM semiconductor-based device (Life Technologies). Additionally, a previously reported ddPCR assay was applied on the same DNA samples using the QX100 Droplet Digital PCR system (BIO-RAD). The diagnostic performance of the mutation allele frequencies (MAFs) determined by these methods was compared with the performance of VUC.
RESULTS: The DNA amount needed for NGS (1-5 ng) and ddPCR (5 ng) was easily available from urinary sediments. The determined detection limit was of 0.4% for the C250T mutation and 0.75% for the C228T mutation in the NGS analyses, whereas it was 1% for both mutations in the ddPCR assay. Of the BCa patients 77.6% and 69.4% were positive for one of the two mutations in the NGS and in the ddPCR, respectively. The concordance between both techniques amounted to 93.1% (rs[0.866, p<0.001) . However, the mutation recovery rate in the urinary DNA was lower in comparison to 85.7% of TERT mutationpositive BCa patients determined in the TUR B specimens. The median of the combined MAFs C228TþC250T was 27.4% (range
